Company intelligence / Profile preview

AM-Pharma Holding

Utrecht, Netherlands

Ownership: Private
Development stage: Other

Overview

Completed Phase 3 REVIVAL study in SA-AKI showed nominally significant reduction in Major Adverse Kidney Events by day 90, though stopped early for futility on 28-day mortality primary endpoint; completed enrollment in Phase 2 study for CSA-RD as of October 2025; Phase 1B ongoing in adult HPP.

Therapeutic areas: CardiovascularNephrologyRare Diseases
Modalities: Recombinant proteinEnzyme replacement therapy
Industry: Biotech

Partnerships

European Investment Bank (EIB)

Beyond the preview

Go deeper on AM-Pharma Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AM-Pharma Holding.

Explore the full profile